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receptors were found to mediate increases, and 5HT2 receptors decreases, in phospho-Ser9-GSK3β levels.
This indicates that serotonergic regulation of the phosphorylation of GSK3β is achieved by a balance between
the opposing actions of these 5HT receptor subtypes. These findings demonstrate for the first time that
serotonergic activity regulates the phosphorylation of GSK3β and show that this regulation occurs in
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Keywords
glycogen synthase kinase-3β, serotonin, 5HT1A receptor, 5HT2 receptor, depression
Comments
This is the accepted manuscript version.
Author(s)
Xiaohua Li, Wawa Zhu, Myoung-Sun Roh, Ari B. Friedman, Kelley Rosborough, and Richard S. Jope
This journal article is available at ScholarlyCommons: http://repository.upenn.edu/hcmg_papers/51
In Vivo Regulation of Glycogen Synthase Kinase-3β (GSK3β) by
Serotonergic Activity in Mouse Brain
Xiaohua Li*,1, Wawa Zhu1, Myoung-Sun Roh1, Ari B Friedman1, Kelley Rosborough1, and
Richard S Jope1
1Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham,
Birmingham, AL, USA
Abstract
The goal of this study was to determine if serotonergic activity, which is impaired in depression,
regulates the phosphorylation of glycogen synthase kinase-3β (GSK3β) in mouse brain in vivo.
GSK3β is inhibited by phosphorylation on serine-9 and is a target of the mood stabilizer lithium.
Following administration to mice of d-fenfluramine to stimulate serotonin (5HT) release and reduce
its reuptake, and clorgyline to inhibit 5HT catabolism, levels of phospho-Ser9-GSK3β were 300–
400% of control levels in the prefrontal cortex, hippocampus, and striatum. Treatment with
monoamine reuptake inhibitors fluoxetine and imipramine also increased the level of phospho-Ser9-
GSK3β. Using receptor selective agonists and antagonists, 5HT1A receptors were found to mediate
increases, and 5HT2 receptors decreases, in phospho-Ser9-GSK3β levels. This indicates that
serotonergic regulation of the phosphorylation of GSK3β is achieved by a balance between the
opposing actions of these 5HT receptor subtypes. These findings demonstrate for the first time that
serotonergic activity regulates the phosphorylation of GSK3β and show that this regulation occurs
in mammalian brain in vivo. These results raise the possibility that impaired inhibitory control of
GSK3β may occur in conditions where serotonergic activity is dysregulated, such as in mood
disorders.
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INTRODUCTION
Glycogen synthase kinase-3 (GSK3) has recently become recognized as a broadly influential
enzyme that modulates many aspects of neuronal function (Grimes and Jope, 2001). GSK3 is
now known to exert profound influences on cellular architecture and plasticity, to regulate
multiple transcription factors and consequently the expression of many genes, and to contribute
to the regulation of apoptosis, and thus cell survival (Frame and Cohen, 2001;Grimes and Jope,
2001). In accordance with these many important actions, the activity of GSK3 is tightly
regulated. The phosphorylation state of GSK3 is the most well-characterized mechanism that
regulates its activity, although regulation of its subcellular distribution and interactions with
GSK3-binding proteins also contribute to controlling its actions (Jope and Johnson, 2004).
Both of the two known isoforms of GSK3 are inhibited by phosphorylation of an N-terminal
serine, which involves serine-9 in GSK3β and serine-21 in GSK3α. This site can be
phosphorylated by several different kinases, including Akt (also known as protein kinase B)
(Cross et al, 1995), protein kinase A (Fang et al, 2000;Li et al, 2000), protein kinase C (Goode
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et al, 1992), and others, indicating that many signaling cascades converge on GSK3 to regulate
its activity. Impairments of this inhibitory control of GSK3 can result in abnormally high GSK3
activity, a condition that can have detrimental effects on neural plasticity, structure, and
survival (Jope and Johnson, 2004). In opposition to the inhibitory N-terminal serine
phosphorylation, tyrosine phosphorylation (tyrosine-216 in GSK3β and tyrosine-279 in
GSK3α) increases the activity of GSK3, but this appears to contribute a lesser regulatory effect
than serine phosphorylation (Frame and Cohen, 2001) and the mechanisms regulating tyrosine
phosphorylation remain unclear. Recently, GSK3β (the isoform most often investigated) has
received much attention from investigators studying mood disorders because the mood
stabilizer lithium was found to be a direct inhibitor of GSK3β, a finding that raised the
possibility that GSK3β may not be adequately controlled in mood disorders (Klein and Melton,
1996;Phiel and Klein, 2001;Jope, 2003).
Impaired monoaminergic neurotransmission has long been linked to depression. This is
indicated in part because the majority of antidepressant drugs increase levels of the
monoamines serotonin (5HT) and/or norepinephrine, and drugs selectively affecting 5HT are
especially in wide use. Thus, pharmacological augmentation of 5HT with monoamine oxidase
(MAO) inhibitors, tricyclic antidepressants, or selective serotonin reuptake inhibitors (SSRIs),
can be therapeutic for depression (Duman et al, 1997). Furthermore, dysregulation of 5HT
neurotransmission in major depression is substantiated by results using a wide variety of
experimental approaches, including studies of 5HT receptors and transporters (Middlemiss et
al, 2002;Stockmeier, 2003), brain imaging and post-mortem studies (Drevets et al,
1999;Ichimiya et al, 2002;Stockmeier, 2003), 5HT metabolism (Owens and Nemeroff,
1994), and neuroendocrine actions (Yatham and Steiner, 1993). Regardless of whether mood
disorders involve impairments in 5HT synthesis, release, or receptor-stimulated actions, any
of these can result in deficient downstream signaling activity. Therefore, clarifying the signals
generated by stimulation of 5HT receptors is an important goal for understanding the
neuropathological underpinnings of mood disorders. Considering the potential importance of
regulating GSK3β in mood disorders suggested by the action of lithium, the present study was
undertaken to determine if serotonergic activity regulates the phosphorylation of GSK3β. For
this purpose, the in vivo phosphorylation of GSK3β was examined in three regions of mouse
brain that are known to express serotonergic receptors, the prefrontal cortex, hippocampus,
and striatum, following administration of agents that alter serotonergic activity.
MATERIALS AND METHODS
Animals and Treatments
Adult, male C57BL/6 mice (Charles River Laboratories, Inc., Wilmington, MA) were treated
with the following agents by intraperitoneal injections: d-fenfluramine (40 mg/kg body
weight), clorgyline (2 mg/kg), 8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT; 0.3–10
mg/kg), WAY100635 (1 mg/kg), LY53857 (0.3–5 mg/kg), 2,5-dimethoxy-4-iodoprenyl-2-
aminopropane (DOI; 20 mg/kg), haloperidol (0.2 mg/kg), imipramine (30 mg/kg; all obtained
from Sigma), and fluoxetine (20 mg/kg; obtained from the National Institute of Mental Health’s
Chemical Synthesis and Drug Supply Program). For intraperitoneal injection of mice, all these
drugs were dissolved in saline, and saline was used as vehicle controls.
Tissue Preparation
Mice were anesthetized with carbon dioxide for 15 s, decapitated, and brain regions were
rapidly dissected in ice-cold saline. Brain regions were homogenized in ice-cold lysis buffer
containing 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.5% NP-40,
10 μg/ml leupeptin, 10 μg/ml aprotinin, 5 μg/ml pepstatin, 0.1 mM β-glycerophosphate, 1 mM
phenylmethanesulfonyl fluoride, 1 mM sodium vanadate, and 100 nM okadaic acid. The lysates
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were centrifuged at 20 800 g for 10 min. Protein concentrations in the supernatants were
determined using the Bradford protein assay (Bradford, 1976).
Immunoblotting
Samples were mixed with Laemmli sample buffer (2% SDS) and placed in a boiling water bath
for 5 min. Proteins were resolved in 10% SDS-polyacrylamide gels, and transferred to
nitrocellulose. Blots were probed with antibodies to phospho-Ser9-GSK3β and total GSK3β
(Cell Signaling Technology, Beverly, MA). Immunoblots were developed using horseradish
peroxidase-conjugated goat anti-mouse, or goat anti-rabbit IgG, followed by detection with
enhanced chemiluminescence, and the protein bands were quantitated with a densitometer.
RESULTS
Serotonergic Activity Regulates GSK3β in Mouse Brain Regions In Vivo
To test if serotonergic signaling activity regulates the phosphorylation of GSK3β in mouse
brain in vivo, d-fenfluramine was administered to mice to stimulate 5HT release and reduce its
reuptake, and 5HT catabolism was inhibited by administration of the MAO inhibitor clorgyline.
Treatment with d-fenfluramine (40 mg/kg, 1 h) alone caused a modest increase in the levels
of phospho-Ser9-GSK3β in mouse prefrontal cortex, hippocampus, and striatum (Figure 1a).
While treatment with clorgyline alone did not change phospho-Ser9-GSK3β levels,
pretreatment with clorgyline (2 mg/kg, 3 h prior to d-fenfluramine) enhanced the increases in
phospho-Ser9-GSK3β levels induced by d-fenfluramine treatment in all three brain regions.
Following combined treatment with clorgyline plus d-fenfluramine these increases amounted
to 410±107% of the control level in the prefrontal cortex (n =11; p<0.01), 425±109% in the
hippocampus (p<0.01), and 313±63% in the striatum (p<0.05) (Table 1). These results reveal
for the first time that serotonergic signaling activity regulates the phosphorylation of GSK3β.
The time dependence of d-fenfluramine-induced increases in phospho-Ser9-GSK3β was
measured in clorgyline-pretreated mice. Administration of d-fenfluramine rapidly and robustly
increased the levels of phospho-Ser9-GSK3β in the prefrontal cortex, hippocampus, and
striatum, while the total level of GSK3β remained unaltered (Figures 1b and c). Maximal
increases in phospho-Ser9-GSK3β were evident in all three brain regions between 0.5 and 1 h
after treatment with d-fenfluramine, followed by a gradual decline towards control levels over
the next several hours.
To test if inhibition of monoamine reuptake alone was sufficient to modulate the
phosphorylation of GSK3, measurements were made in prefrontal cortex 1 h following
administration of fluoxetine (20 mg/kg), an SSRI, or imipramine (30 mg/kg), a tricyclic
antidepressant that inhibits the reuptake of both 5HT and norepinephrine (Figure 2). Both
treatments caused significant increases in the level of phospho-Ser9-GSK3β, which reached
229±39% of the control level (n =10, p<0.05) after fluoxetine treatment and 268±47% of the
control level (n =4, p<0.05) after imipramine treatment, whereas the total levels of GSK3β
were not changed. In contrast to fluoxetine and imipramine, administration of the antipsychotic
haloperidol (0.2 mg/kg) had no effect on the level of phospho-Ser9-GSK3β.
5HT1A Receptor Activation Increases Phospho-Ser9-GSK3β
5HT1A receptor-selective agents were used to begin to investigate the 5HT receptor subtypes
that mediate the in vivo 5HT-induced increase in phospho-Ser9-GSK3β. Administration of the
5HT1A receptor antagonist WAY100635 (1 mg/kg; 2 h) alone had no significant effect on the
level of phospho-Ser9-GSK3β (Figure 3a, Table 1). However, pretreatment with WAY100635
greatly attenuated the increase in phospho-Ser9-GSK3β levels caused by administration of
clorgyline plus d-fenfluramine in prefrontal cortex, hippocampus, and striatum (Figures 3a and
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b). Conversely, treatment with the 5HT1A receptor agonist 8-OH-DPAT (10 mg/kg; 1 h) alone
significantly increased the level of phospho-Ser9-GSK3β in all three brain regions (Figure 3a).
These increases amounted to 240±55% of the control level in the prefrontal cortex (p<0.05;
n=7), 239±35% in the hippocampus (p<0.05), and 362±94% in the striatum (p<0.05) (Table
1). Examination of the dose-response to 8-OH-DPAT revealed that a dose as low as 0.3 mg/
kg (hippocampus) or 1 mg/kg (prefrontal cortex and striatum) caused increased phospho-Ser9-
GSK3β, while the total level of GSK3β was unaltered (Figure 3c). These results indicate that
activation of 5HT1A receptors increases phospho-Ser9-GSK3β in mouse brain in vivo.
Phospho-Ser9-GSK3β is Increased by Blocking 5HT2 Receptors
To examine if regulation of 5HT2 receptors influences the phosphorylation of GSK3β, we
utilized the 5HT2 receptor agonist DOI and antagonist LY53857. Whereas activation of 5HT2
receptors with DOI (20 mg/kg; 1 h) did not change phosphorylation of GSK3β (Figure 4a,
Table 1), administration of LY53857 (5 mg/kg; 2 h) alone caused a large increase in phospho-
Ser9-GSK3β in prefrontal cortex (346±97% of control level, n=7, p =0.055), hippocampus
(193±30%; p<0.05), and striatum (378±60; p<0.01) without changing the total level of
GSK3β (Figure 4a, Table 1). The duration of the increased phospho-Ser9-GSK3β following
blockade of 5HT2 receptors was examined by making measurements 1, 2, 4, 6, and 24 h after
a single administration of LY53857 (5 mg/kg) (Figure 4b). Treatment with LY53857 caused
a rapid and prolonged increase in phospho-Ser9-GSK3β in all three brain regions followed by
a return to control levels after 24 h. Examination of the dose–response to LY53857
demonstrated that increased phosphorylation of GSK3β was dose dependent with the effects
more prominent in the prefrontal cortex and striatum than in the hippocampus (Figure 4c). The
lack of an effect of DOI and the increases in phospho-Ser9-GSK3β caused by LY53857 indicate
that endogenous activity of 5HT2 receptors contributes to the maintenance of dephosphorylated
GSK3β and that maximal signaling of 5HT2 receptors to reduce phospho-Ser9-GSK3β was
achieved by endogenous 5HT in the absence of further stimulation.
These findings were used to examine the effect of blocking 5HT2 receptors, which normally
mediate dephosphorylation of GSK3β, on the phosphorylation of GSK3β caused by stimulating
serotonergic activity. Pretreatment with LY53857 to block 5HT2 receptors followed by
administration of clorgyline plus d-fenfluramine resulted in a very large increase in phospho-
Ser9-GSK3β (Figure 4d). This supports the conclusion that activation of 5HT2 receptors
following administration of clorgyline plus d-fenfluramine was inhibitory towards the
phosphorylation of GSK3β, an effect opposite to that of 5HT1A receptors. To further examine
these opposing actions of the 5HT1A and 5HT2 receptors, 5HT1A receptors were stimulated
by administration of 8-OH-DPAT and 5HT2 receptors were blocked by treatment with
LY53857. These results showed that blocking 5HT2 receptors allowed a greater 8-OH-DPAT-
induced increase in phospho-Ser9-GSK3β than was caused by administration of the 5HT1A
agonist alone (Figure 4e). Taken together, these results demonstrate that serotonergic
regulation of phospho-Ser9-GSK3β is achieved by a balance between the opposing actions of
5HT1A and 5HT2 receptors (Figure 5).
DISCUSSION
The results of this study show that enhanced serotonergic activity in several regions of mouse
brain increases the inhibitory Ser9-phosphorylation of GSK3β. It is of interest that this effect
also is caused in vivo by a therapeutically relevant concentration of lithium (De Sarno et al,
2002). Examination of receptor subtypes involved in the serotonergic regulation of phospho-
Ser9-GSK3β revealed that stimulation of 5HT1A receptors causes phosphorylation of
GSK3β, whereas 5HT2 receptor stimulation mediates dephosphorylation of GSK3β. Thus, the
balance between the activities of these 5HT receptors can modulate GSK3β in vivo.
Li et al. Page 4
Neuropsychopharmacology. Author manuscript; available in PMC 2007 September 19.
Previous studies have provided evidence that 5HT1A receptors are deficient in major
depressive disorder, although this remains a subject of intense investigation (reviewed in
Stockmeier, 2003). For example, positron emission tomography measurements of brain
5HT1A receptors identified widespread reductions associated with major depressive disorder
(Drevets et al, 1999;Sargent et al, 2000). Furthermore, a recent report showed that 5HT1A
receptor-coupled activation of signal transduction systems was reduced in post-mortem brain
samples from depressed suicide victims compared with matched controls (Hsiung et al,
2003). Also relevant was their finding that Akt activity is substantially lower in post-mortem
brain samples from depressed suicide victims than in control samples (Hsiung et al, 2003).
This is of interest because Akt normally causes inhibitory Ser9-phosphorylation of GSK3β
(Cross et al, 1995), so its impairment also could contribute to abnormally active GSK3β. Our
finding that stimulation of 5HT1A causes Ser9-phosphorylation (inactivation) of GSK3β,
raises the possibility that low 5HT1A activation in depression may result in deficient inhibitory
control of GSK3β through impaired phosphorylation, resulting in abnormally active GSK3β.
However, this postulate is difficult to address directly because we previously found that
phospho-Ser9-GSK3β is dephosphorylated post mortem and large variations were observed
among post-mortem samples from human subjects (Lesort et al, 1999, and unpublished
observations). Only with the development of new methodologies will experiments be able to
accurately measure the activity or phosphorylation state of GSK3β in human brain samples.
Opposite to the downregulated 5HT1A receptors, there is substantial evidence that 5HT2
receptors are upregulated in depression (reviewed in Stockmeier, 2003). The present study
found that stimulation of 5HT2 receptors supports dephosphorylation (activation) of GSK3β.
Thus, it can be surmised that upregulated 5HT2 receptors in depression may be associated with
abnormal increases in GSK3β activity in depression. The results also showed that endogenous
serotonergic activity, in the absence of any stimulant, acts predominantly through 5HT2
receptors to keep GSK3β dephosphorylated because treatment with the 5HT2 antagonist
LY53857 increased phospho-Ser9-GSK3β, whereas treatment with the 5HT1A receptor
antagonist WAY100635 had no effect without additional serotonergic stimulation. The basal
5HT2 receptor-mediated dephosphorylation of GSK3β was maximal, because it was unaltered
by administration of the 5HT2 agonist DOI. In contrast, the 5HT1A receptor effect could be
activated further by stimulation, because administration of the 5HT1A agonist 8-OH-DPAT
increased phospho-Ser9-GSK3β, and serotonergic stimulation (with administration of
clorgyline plus d-fenfluramine or 5HT reuptake inhibitors) increased phospho-Ser9-GSK3β,
an increase that was greatly attenuated by the 5HT1A receptor antagonist WAY100635. Taken
together, reduced signaling capacity of 5HT1A receptors which would disable inhibitory
regulation of GSK3β, and increased signaling capacity of 5HT2 receptors which activate
GSK3β, by acting together could cause a substantial increase in GSK3β activity in main
depression. It is not yet known whether these modulatory effects of serotonergic activity on
GSK3β emanate directly from 5HT receptor-coupled signaling pathways or if they reflect
changes in the activities of neuronal circuits influenced by 5HT, a question that is currently
under investigation.
These findings suggest the possibility that reduced serotonergic activity, as appears to occur
in depression, is associated with deficient inhibitory control of GSK3β, raising the question of
how this condition would affect neuronal function. The answer to this rests with what is known
about the actions of GSK3β. This enzyme has extensive effects on neuronal function, including
influences on gene expression through the regulation of at least 15 different transcription
factors (Jope and Johnson, 2004). Equally important, GSK3β extensively influences neuronal
architecture, plasticity, intracellular transport mechanisms, and even survival, generally
impairing these events (Grimes and Jope, 2001), so modulation of GSK3 activity can underlie
structural dynamics and neural plasticity over time. This may go so far as to include neuronal
survival, a relevant possibility because imaging and post-mortem studies indicate that
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depression is associated with cell loss (Rajkowska, 2002) and GSK3 is well known to promote
cell death (Grimes and Jope, 2001). Thus, hyperactive GSK3β associated with dysregulated
serotonergic activity could detrimentally affect neuronal structure, plasticity, and survival, and
may be amenable to regulation by antidepressant treatments, which is currently under
investigation.
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Figure 1.
Serotonergic stimulation increases phospho-Ser9-GSK3β in vivo. (a) Mice were treated with
d-fenfluramine (d-FEN; 40 mg/kg, 1 h), clorgyline (CLG; 2 mg/kg; 3 h prior to d-FEN), or
CLG alone (4 h), and phospho-Ser9-GSK3β levels were measured by immunoblot analysis in
prefrontal cortex (PFC), hippocampus (HIP), and striatum (STR). (b) Representative
immunoblots of phospho-Ser9-GSK3β (left) and total levels of GSK3β (right), and (c)
quantitation of phospho-Ser9-GSK3β levels, showing the time dependence of d-FEN-induced
increases in phospho-Ser9-GSK3β in CLG-pretreated mice. Values from a representative
experiment are shown as the percent of control values from vehicle (saline)-treated mice, and
values at 0 h were obtained in samples from mice treated with CLG alone.
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Figure 2.
Monoamine reuptake inhibitors increase phospho-Ser9-GSK3β in vivo. (a) Representative
immunoblots of phospho-Ser9-GSK3β and total GSK3β, and (b) quantitative values of
phospho-Ser9-GSK3β level (percent of saline control), in PFC 1 h after treatment with saline
(Ctr), fluoxetine (FLX; 20 mg/kg; n=10), imipramine (IMI; 30 mg/kg; n=4), or haloperidol
(HAL; 0.2 mg/kg). Means±SEM; *p<0.05 compared with control (saline) values (ANOVA).
Li et al. Page 9
Neuropsychopharmacology. Author manuscript; available in PMC 2007 September 19.
Figure 3.
Phospho-Ser9-GSK3β is increased by stimulation of 5HT1A receptors. (a) Phospho-Ser9-
GSK3β was measured in PFC, HIP, and STR following administration of the 5HT1A receptor
antagonist WAY100635 (1 mg/kg; 2 h), CLG (2 mg/kg) 3 h prior to d-FEN (40 mg/kg; 1 h),
CLG 3 h and WAY 100635 1 h prior to d-FEN, or the 5HT1A receptor agonist 8-OH-DPAT
(10 mg/kg; 1 h). The total level of GSK3β also was measured in each sample and was not
changed by any of these treatments (data not shown). (b) Quantitative values (given as the
percent of saline controls) of the stimulation of phospho-Ser9-GSK3β following treatment with
CLG prior to d-FEN (shaded bars) and the attenuation of that stimulation provided by
pretreatment with WAY100635 (black bars) (treatment protocols as described in (a)) in PFC,
HIP, and STR. Means±SEM. *p<0.05 compared with control (saline) values (ANOVA). (c)
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Immunoblots and quantitative values of concentration-dependent effects of treatment with 8-
OH-DPAT (0, 0.3, 1.0, and 3.0 mg/kg; 1 h) on phospho-Ser9-GSK3β (closed circles) and total
GSK3β (open circles) in PFC, HIP, and STR. Values from a representative experiment are
shown as the percent of values from control (saline-treated) mice.
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Figure 4.
Phospho-Ser9-GSK3β is increased by blocking 5HT2 receptors. (a) Phospho-Ser9-GSK3β was
measured by immunoblots in PFC, HIP, and STR following administration of the 5HT2
receptor agonist DOI (20 mg/kg; 1 h) or the 5HT2 receptor antagonist LY53857 (5 mg/kg; 2
h). Immunoblots of total GSK3β show that it was unaltered by treatment with LY53857. (b)
Quantitation of phospho-Ser9-GSK3β levels, showing the duration of increases in phospho-
Ser9-GSK3β induced by LY53857 (5 mg/ kg) in three mouse brain regions. (c) Concentration-
dependent effects of treatment with LY53857 (0, 0.3, 1, 3, and 5 mg/kg; 2 h) on phospho-Ser9-
GSK3β. Values in (b) and (c) are shown as the percent of values from control (saline-treated)
mice. (d) LY53857 was administered 1 h prior to treatment with d-FEN (40 mg/kg, 1 h) in
CLG-pretreated mice. (e) 8-OH-DPAT (10 mg/kg; 1 h) was administered alone or 1 h after
LY53857 (5 mg/ kg; 2 h).
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Figure 5.
Schematic depiction of the regulation of GSK3β activity by 5HT1A and 5HT2 receptors.
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